Article Figures & Data
Figures
- FIGURE 1.
Treatment with CTLA4-Ig abrogates the cytotoxic activity of BAL lymphocytes, whereas Y100F-Ig has marginal effects. C57BL/6J mice (five per group) were infected intranasally with 12 HAU of influenza virus. Mice were treated i.p with either CTLA4-Ig, Y100F-Ig, or L6-Ig every 48 h beginning the day before infection. BAL cells were collected on day 9 after infection, pooled, and depleted of macrophages by plastic adherence. Cytotoxic activity was measured using a JAM test. The filled symbols represent killing of EL4 target cells coated with NP366-374, and the open symbols represent killing of EL4 targets without peptide.
- FIGURE 2.
Treatment with CTLA4-Ig markedly reduces the cytotoxicity of in vitro stimulated splenocytes, whereas Y100F-Ig has no effect. Mice (four per group) were treated with CTLA4-Ig, Y100F-Ig, or L6-Ig and infected with influenza virus as detailed in the legend to Fig. 1. Splenocytes were obtained from groups of mice 9 days after infection and restimulated in vitro with 0.1 μM NP366-374. After 5 days of culture, cells were tested for cytotoxic activity by a JAM test. The filled symbols represent killing of EL4 target cells coated with NP366-374, and the open symbols represent killing of EL4 targets without peptide.
- FIGURE 3.
Treatment with CTLA4-Ig or Y100F-Ig reduces the number of Ag-specific IFN-γ-secreting cells in the BAL. Mice (three per group) were treated with CTLA4-Ig, Y100F-Ig, or L6-Ig and infected with influenza virus as detailed in the legend to Fig. 1. Freshly isolated BAL cells were collected on day 9 after infection, pooled, and depleted of macrophages by plastic adherence. The filled bars represent the number of IFN-γ-secreting cells/106 cells after a 6-h restimulation with NP366-374. The open bars represent the number of IFN-γ-secreting cells/106 cells after a 6-h incubation without peptide.
- FIGURE 4.
Treatment with CTLA4-Ig or Y100F-Ig reduces the accumulation of Vβ8.3+CD8+ cells in the BAL and lung. Mice (three per group) were treated with CTLA4-Ig, Y100F-Ig, or L6-Ig and infected with influenza virus as detailed in the legend to Fig. 1. Freshly isolated BAL cells and lung-infiltrating lymphocytes were collected at the indicated time points after infection, pooled, and depleted of macrophages by plastic adherence. The percentages of CD4+ cells (open bars) and CD8+ cells (filled bars) which were Vβ8.3+ were determined by FACS analysis.
- FIGURE 5.
Treatment with CTLA4-Ig reduces the titer of virus-specific IgG1 and IgG2a, whereas Y100F-Ig has no effect. Mice were treated with CTLA4-Ig, Y100F-Ig, or L6-Ig and infected with influenza virus as detailed in the legend to Fig. 1. Serum was collected at day 12 after infection, and virus-specific Ab levels were determined by ELISA. Symbols represent serum Ab titers from individual mice; the horizontal line represents the geometric mean for each group.
- FIGURE 6.
Treatment with CTLA4-Ig delays the clearance of virus from infected lungs, whereas Y100F-Ig has no effect. Groups of mice were treated with CTLA4-Ig, Y100F-Ig, or L6-Ig and infected with influenza virus as detailed in the legend to Fig. 1. Titers of infectious HKx31 virus in lung extracts, obtained from individual mice at the indicated time points after infection, were determined in the Madin-Darby kidney cell assay. Symbols represent virus titers from individual mice.
In this issue
